Clearbridge Investments LLC Has $312.94 Million Holdings in Haleon plc (NYSE:HLN)

Clearbridge Investments LLC reduced its position in shares of Haleon plc (NYSE:HLN) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,803,243 shares of the company’s stock after selling 4,567,165 shares during the quarter. Clearbridge Investments LLC owned 0.72% of Haleon worth $312,943,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Addison Advisors LLC raised its stake in shares of Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock worth $47,000 after purchasing an additional 1,106 shares in the last quarter. Synovus Financial Corp increased its stake in shares of Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after purchasing an additional 1,216 shares during the last quarter. Haverford Trust Co raised its holdings in shares of Haleon by 5.0% during the 4th quarter. Haverford Trust Co now owns 25,842 shares of the company’s stock valued at $247,000 after purchasing an additional 1,233 shares in the last quarter. Greenleaf Trust raised its holdings in shares of Haleon by 8.4% during the 4th quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock valued at $164,000 after purchasing an additional 1,333 shares in the last quarter. Finally, Baron Wealth Management LLC lifted its stake in shares of Haleon by 4.3% in the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after purchasing an additional 1,381 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Price Performance

Shares of Haleon stock opened at $10.24 on Friday. Haleon plc has a twelve month low of $7.99 and a twelve month high of $10.80. The firm has a market cap of $46.33 billion, a P/E ratio of 30.10, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The firm’s 50-day simple moving average is $9.94 and its 200-day simple moving average is $9.87. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, research analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is 58.97%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. HSBC reaffirmed a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Finally, Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haleon has a consensus rating of “Hold” and a consensus target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.